DOP048: Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with Inflammatory Bowel DiseaseECCO'18 Vienna 2018
1
DOP049: Combination therapy of cyclosporine and vedolizumab is effective and safe for severe, steroid-resistant Ulcerative Colitis patients: A prospective studyECCO'18 Vienna 2018
1
DOP050: Influence of disease location on vedolizumab efficacy in Inflammatory Bowel Disease: A real-life multicentre experienceECCO'18 Vienna 2018
1
DOP051: Shorter disease duration is associated with higher response rates to vedolizumab in Crohn’s Disease but not Ulcerative Colitis: A multi-centre consortium analysisECCO'18 Vienna 2018
1
DOP052: Vedolizumab versus ustekinumab for Crohn's Disease: Comparative effectiveness in a real-life observational cohort study (ICC Case Series)ECCO'18 Vienna 2018
1
DOP053: Impact of concomitant immunomodulator use on vedolizumab effectiveness: A multicentre consortium propensity score–matched analysisECCO'18 Vienna 2018
1
DOP054: Vedolizumab in combination with steroids for induction therapy in Crohn’s Disease: An exploratory analysis of the GEMINI 2 and GEMINI 3 studiesECCO'18 Vienna 2018
1
DOP055: Luminal application of a GATA3-specific DNAzyme ameliorates mucosal inflammation in a randomised trial with active Ulcerative Colitis patientsECCO'18 Vienna 2018
1
DOP058: Combined stem cells and anticytokine therapy contributes to a more pronounced decrease in the degree of inflammation of the intestinal mucosa in Crohn's DiseaseECCO'18 Vienna 2018
1
DOP059: Combined anticytokine and local mesenchymal stem cells therapy promotes longer healing of simple fistulas in patients with Crohn's DiseaseECCO'18 Vienna 2018
1
DOP061: Human amnion epithelial cells reduce intestinal inflammation in a 2,4,6-trinitrobenzene sulfonic acid induced model of Acute ColitisECCO'18 Vienna 2018
1
DOP062: The anti-MAdCAM antibody SHP647 in Crohn’s Disease: Endoscopic effects of induction therapyECCO'18 Vienna 2018
1
DOP064: ECCO expert consensus and topical review on treatment exit strategies in Inflammatory Bowel DiseaseECCO'18 Vienna 2018
1
DOP065: Long term cost effectiveness of tight control for Crohn’s Disease with adalimumab-based treatment: Economic evaluation beyond 48 weeks of CALM trialECCO'18 Vienna 2018
1